Radioimmunotherapy for lymphoma

Current Opinion in Oncology

Volumn 11, Issue 5, 1999, Pages 375-380

  Zelenetz, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RADIOISOTOPE;

HUMAN; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

CLINICAL TRIALS; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY;

EID: 0032848896     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199909000-00009     Document Type: Review

References (25)

1. 90Y-lymphoma therapy. Cancer 1994, 73:966-973. This paper demonstrates the mechanisms of cell kill by low-dose rate radiation therapy. The authors find that induction of apoptosis is the major mediator of cytotoxicity.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
3. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
4. Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, et al.: Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993, 11:2021-2029.
5. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329:1219-1224. This was the landmark report demonstrating that RIT used in a myeloablative sotting was not only feasible but was effective for both low-grade and intermediate-grade lymphoma.
6. 131l-anti-B1. The data demonstrate that a single nonmyeloablative of radio-labeled antibody is effective in the treatment of NHL.
7. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, et al.: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2. an anti-CD22 monoclonal antibody. Cancer Res 1995, 55(suppl):5899-5907.
8. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al.: Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995, 86: 4063-4070.
9. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al.: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996, 2:457-470.
10. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al.: Maximum-tolerated dose, toxicity, and efficacy of (131)l-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998, 16:3246-3256.
11. Maloney DG: Advances in immunotherapy of hematologic malignancies. Curr Opin Hematol 1998, 5:237-243.
12. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, et al.: Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998, 51:364-369.
13. Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, et al.: Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998, 89:748-756.
14. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-1652.
15. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998, 16:3270-3278.
16. Kaminski MS, Vose J, Saleh M, Lister A, Knox S, Crowther D, et al.: A multicenter phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients with chemotherapy-relapsed/refractory low-grade or transformed low grade B cell non-Hodgkin's lymphoma. Blood 1997, 2268.
17. Kaminski MS, Zelenetz AD, Press O, Saleh M, Leonard J, Fehrenbacher L, et al.: Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 1998, 92:1296.
18. Witzig TE, White CA, Wiseman GA, Gordon L, Emmanouilides C, Raubitschek A, et al.: Commonly used response criteria for non-Hodgkin's lymphoma (NHL) applied to IDEC-Y2B8 radioimmunotherapy trial: importance of "normal" lymph node size. Proc Ann Meet Am Soc Clin Oncol 1999, 14:152.
19. Wiseman GA, White CA, Stabin M, Gordon L, Emmanouilides C, Raubitschek A, et al.: Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than to normal organs. Proc Ann Meet Am Soc Clin Oncol 1999, 14:13.
20. Lamborn KR, DeNardo GL, DeNardo SJ, Goldstein DS, Shen S, Larkin EC, Kroger LA: Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res 1997, 3:1253-1260.
21. Simpkin DJ, Mackie TR: EGS4 Monte Carlo determination of the beta dose kernel in water. Med Phys 1990, 17:179-186.
22. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer 1997, 80:2706-2711.
23. Denardo GL, Denardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, et al.: Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res 1998, 18:2779-2788.
24. Czuczman MS, Nabi HA, Meredith RM, Blend M, Riva P, Hughes L, et al.: Radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Immunother 1994, 16:160.
25. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, et al.: Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998, 4:2691-2700.